[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,223,585
  • Shares Outstanding, K 14,408
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,720 K
  • EBIT $ -58 M
  • EBITDA $ -58 M
  • 60-Month Beta -0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.80

Options Overview Details

View History
  • Implied Volatility 53.31% (+53.31%)
  • Historical Volatility 94.97%
  • IV Percentile 2%
  • IV Rank 1.30%
  • IV High 246.56% on 02/17/26
  • IV Low 50.76% on 08/19/26
  • Expected Move (DTE 22) 13.45 (8.94%)
  • Put/Call Vol Ratio 0.70
  • Today's Volume 85
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 943
  • Open Int (30-Day) 2,521
  • Expected Range 136.88 to 163.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.63
  • Number of Estimates 4
  • High Estimate $-1.05
  • Low Estimate $-1.98
  • Prior Year $-1.03
  • Growth Rate Est. (year over year) -58.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.30 +11.11%
on 08/04/26
160.47 -6.32%
on 08/06/26
+8.56 (+6.04%)
since 07/27/26
3-Month
100.00 +50.33%
on 06/10/26
161.38 -6.85%
on 06/30/26
+34.07 (+29.31%)
since 05/27/26
52-Week
49.81 +201.83%
on 08/29/25
161.38 -6.85%
on 06/30/26
+93.88 (+166.31%)
since 08/27/25

Most Recent Stories

More News
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics: Q2 Earnings Snapshot

Palvella Therapeutics: Q2 Earnings Snapshot

PVLA : 150.33 (-2.59%)
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors

Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company...

PVLA : 150.33 (-2.59%)
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted...

PVLA : 150.33 (-2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 168.50
2nd Resistance Point 161.62
1st Resistance Point 157.98
Last Price 150.33
1st Support Level 147.45
2nd Support Level 140.57
3rd Support Level 136.93

See More

52-Week High 161.38
Last Price 150.33
Fibonacci 61.8% 118.76
Fibonacci 50% 105.59
Fibonacci 38.2% 92.43
52-Week Low 49.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.